Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: dose-efficacy studies upon oral administration
H. TANI, T. Komeno, A. Fukuma, S. Fukushi, S. Taniguchi, M. Shimojima, A. Uda, S. Morikawa, N. Nakajima, Y. Furuta, M. Saijo
This study shows that oral favipiravir at 120 or 200 mg/kg/day effectively treats SFTSV infection in IFNAR-/- mice when started within 4 days post-infection, preventing mortality.
bioRxiv · Aug 24, 2018Microbiology